A
grade
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
Survodutide (BI 456906) · The New England journal of medicine · 2023 · RCT · Phase 3 · n=752Top journal
Survodutide at doses of 3.6 mg and 6.0 mg resulted in significant weight loss in adults with obesity and type 2 diabetes compared to placebo over 76 weeks.
-8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2.